logo

For the Inventor, By the Inventor

Hofheim am Taunus, Germany

Klaus U Weithmann

This inventor holds 19 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Hoechst Aktiengesellschaft, Hoechst Roussel Pharmaceuticals, Hoeschst Aktiengesellschaft. Active years: 1982-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klaus U Weithmann. Retrieved from https://idiyas.com/inventor/klaus-u-weithmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19

% Patents Active = 100.0

Average Co-Inventor Count = 2.2

ph-index = 6

Forward Citations = 135(Granted Patents)


Location History:

  • Eppstein, DE (1982)
  • Hofheim, DE (1996 - 1998)
  • Hofheim am Taunus, DE (1987 - 2000)

Company Filing History:

goldMedal18 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents
silverMedal1 out of 539 
 
Hoechst Roussel Pharmaceuticals
 patents
bronzeMedal1 out of 15 
 
Hoeschst Aktiengesellschaft
 patents
where one patent can have more than one assignee

Years Active: 1982-2000

Loading Chart...
Areas of Expertise:
Arylcycloalkyl Derivatives
Leflunomide
Phosphonoacetic Acid
Skin Disorders
Thiazoles
Fatty Acids
Tumor Necrosis Factor
Antiaggregatory Effect
Pentoxifylline
Prostaglandin
Pharmaceutical Combinations
Inflammation Treatment
19 patents (USPTO):Explore Patents
1. 6159988 - Arylcycloalkyl derivatives, their production and their use (2000-12-12),
2. 5814627 - 3, 5-disubstituted and 3, 4, 5-trisubstituted 2-isoxazolines and (1998-09-29),
3. 5776977 - Arylcycloalkyl derivatives, their production and their use (1998-07-07),
4. 5627173 - Phosphonoacetic acid derivatives and their use for treating degenerative (1997-05-06),
5. 5589514 - Arylcycloalkyl derivatives, their production and their use (1996-12-31),
6. 5556870 - Use of leflunomide for inhibiting interleukin 1 beta (1996-09-17),
7. 5554637 - Use of leflunomide for inhibiting interleukin 1 alpha (1996-09-10),
8. 5547971 - Use of leflunomide for inhibiting interleukin 8 (1996-08-20),
9. 5547970 - Use of leflunomide for inhibiting tumor necrosis factor alpha (1996-08-20),
10. 5504084 - Pharmaceutical for the treatment of skin disorders (1996-04-02),
11. 5137897 - 2-substituted 4-(3-alkyl-5-tert.-butyl-4-hydroxyphenyl) thiazoles, (1992-08-11),
12. 5043328 - Formulations containing unsaturated fatty acids for the synthesis of (1991-08-27),
13. 4983514 - Method for detecting the antiaggregatory effect of vasoactive (1991-01-08),
14. 4975432 - Method of using pentoxifylline for treating inflammation (1990-12-04),
15. 4904648 - Pharmaceutical preparations for induction of labor and for contraceptive (1990-02-27),

Title: Klaus U. Weithmann: A Pioneer in Pharmaceutical Innovations

Introduction

Klaus U. Weithmann is a distinguished inventor located in Hofheim am Taunus, Germany. With an impressive portfolio of 19 patents, he has significantly contributed to the field of pharmaceuticals. His innovations focus on compounds that show promising activities against various inflammatory conditions.

Latest Patents

Among Klaus's latest patents is a noteworthy invention involving Arylcycloalkyl derivatives, including their production and use. The compounds, defined by specific formula I, have been discovered to possess activity against inflammatory conditions. Additionally, he has developed 3, 5-disubstituted and 3, 4, 5-trisubstituted 2-isoxazolines, which further emphasize his expertise in creating vital pharmaceutical compounds.

Career Highlights

Throughout his career, Klaus has made significant strides in the pharmaceutical industry. He has worked with reputable companies such as Hoechst Aktiengesellschaft, a prominent player in the field of healthcare and pharmaceuticals. His work at these institutions has allowed him to harness his innovative potential and bring impactful inventions to fruition.

Collaborations

Klaus has had the privilege to collaborate with several notable coworkers, including Robert R. Bartlett and Dirk Seiffge. These collaborations have likely enabled the exchange of ideas and expertise, further enhancing the quality and reach of his inventions.

Conclusion

Klaus U. Weithmann stands out as a pivotal figure in pharmaceutical innovation, with a focus on creating compounds that address pressing health issues. His extensive patent portfolio and collaborations signify his dedication to advancing medical science and improving patient care through innovative solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…